UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-0571538 (State or other ju ...

SEPTEMBER 2021 ARCADIA BIOSCIENCES INVESTOR PRESENTATION FORWARD LOOKING STATEMENTS • "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements about the company and its products, including statements relating to components of the company's long-term financial success; the company's traits, commercial products, and collaborations; the company's ability to manage the regulatory processes for its traits and commercial products; th ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q2 2021 Earnings Conference Call August 16, 2021 4:30 PM ET Company Participants Matt Plavan – President and Chief Executive Officer Pam Haley – Chief Financial Officer Conference Call Participants Ryan Meyers – Lake Street Capital Operator Good afternoon and welcome to Arcadia Biosciences' Second Quarter 2021 Earnings Conference Call. Today's presenters will be Matt Plavan, President and CEO; and Pam Haley, Chief Financial Officer of Arcadia. This call is being webca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-0571538 (State or other jurisdi ...

ARCADIA BIOSCIENCES Q1 2021 Earnings Call May 17, 2021 FORWARD LOOKING STATEMENTS • "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements about the company and its products, including statements relating to projected revenue growth as a result of the asset acquisition; synergies between Arcadia's business and the purchased assets; the company's anticipated financial results; the projected size of the CBD market; current and ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q1 2021 Earnings Conference Call May 17, 2021 4:30 PM ET Company Participants Matt Plavan – President and Chief Executive Officer Pam Haley – Chief Financial Officer Conference Call Participants Ben Klieve – Lake Street Capital Steven Ralston – Zacks Operator Good afternoon and welcome to Arcadia Biosciences' First Quarter 2021 Earnings Conference Call. Today's presenters will be Matt Plavan, President and CEO; and Pam Haley, CFO of Arcadia. This call is being webcast ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-37383 Arcadia Biosciences, Inc. WASHINGTON, DC 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) For the transition period from to ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR (Exact Name of Registrant as Specified in its Charter) Delaware 81-0571538 (State or other jurisd ...

Table of Contents (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37383 Arcadia Biosciences, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction ...

Call Start: 16:30 January 1, 0000 5:11 PM ET Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2020 Earnings Conference Call March 29, 2021 16:30 ET Company Participants Matthew Plavan - President & Chief Executive Officer Randy Shultz - Chief Technical Technology Officer Pam Haley - Chief Financial Officer Conference Call Participants Ben Klieve - Lake Street Capital Steven Ralston - Zacks Operator Good afternoon, and welcome to Arcadia Biosciences Year-End 2020 Earnings Conference Call. Today's presenters will b ...

MARCH 9-10, 2021 | --- | --- | --- | --- | |---------------------------------------|-------|-------|-------| | | | | | | ARCADIA BIOSCIENCES | | | | | H.C. WAINWRIGHT GLOBAL LIFE SCIENCES | | | | | CONFERENCE | | | | FORWARD LOOKING STATEMENTS • "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements about the company and its products, including statements relating to components of the company's long-term financial success; th ...